cGAS-STING signaling pathway in MASLD and liver fibrosis

Area of Science:

• Hepatology
• Immunology
• Cell Biology

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) involves lipid accumulation and inflammation.
• This triggers damage-associated molecular patterns, activating the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway.
• The cGAS-STING pathway is implicated in liver cell fate alterations within MASLD.

Purpose of the Study:

• To review the role of the cGAS-STING signaling pathway in liver cells during MASLD.
• To examine the pathway's impact on cell fate and liver fibrosis.
• To explore therapeutic potential targeting the cGAS-STING pathway for MASLD and fibrosis.

Main Methods:

• Literature review of studies on cGAS-STING signaling in MASLD.
• Analysis of evidence linking cGAS-STING activation to liver cell types (Kupffer cells, hepatic stellate cells, hepatocytes, liver sinusoidal endothelial cells).
• Synthesis of information on the pathway's contribution to MASLD pathogenesis and fibrosis progression.

Main Results:

• The cGAS-STING pathway is activated in multiple liver cell types during MASLD.
• Activation of cGAS-STING signaling influences liver cell fate.
• This pathway is associated with the development of liver fibrosis in the context of MASLD.

Conclusions:

• The cGAS-STING signaling pathway plays a significant role in liver cell responses within MASLD.
• Understanding the cGAS-STING pathway's function in cell fate is crucial for MASLD and fibrosis.
• Targeting the cGAS-STING pathway presents a promising therapeutic strategy for MASLD and liver fibrosis.